BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $98.16, for a total transaction of $147,240.00. Following the completion of the transaction, the chief executive officer now owns 286,790 shares in the company, valued at $28,151,306.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Monday, July 23rd, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $101.69, for a total transaction of $152,535.00.

Shares of NASDAQ BMRN traded up $1.66 during trading on Friday, hitting $97.82. 39,199 shares of the company were exchanged, compared to its average volume of 888,106. The firm has a market capitalization of $17.16 billion, a P/E ratio of -146.12 and a beta of 1.63. BioMarin Pharmaceutical Inc. has a 1 year low of $75.81 and a 1 year high of $106.20. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.24 and a current ratio of 2.83.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The company had revenue of $372.80 million for the quarter, compared to analysts’ expectations of $359.25 million. BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. BioMarin Pharmaceutical’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post -0.24 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, September 1st. TheStreet upgraded shares of BioMarin Pharmaceutical from a “d+” rating to a “c-” rating in a research report on Friday, August 17th. Citigroup lifted their price objective on shares of BioMarin Pharmaceutical from $108.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Finally, Wedbush reiterated an “outperform” rating and issued a $120.00 price objective (up from $115.00) on shares of BioMarin Pharmaceutical in a research report on Monday, August 6th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. BioMarin Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $116.28.

Hedge funds and other institutional investors have recently modified their holdings of the business. Nissay Asset Management Corp Japan ADV boosted its position in shares of BioMarin Pharmaceutical by 4.8% during the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 12,078 shares of the biotechnology company’s stock worth $1,138,000 after purchasing an additional 556 shares in the last quarter. Scout Investments Inc. raised its stake in shares of BioMarin Pharmaceutical by 125.6% during the 2nd quarter. Scout Investments Inc. now owns 214,099 shares of the biotechnology company’s stock worth $20,168,000 after buying an additional 119,185 shares during the last quarter. International Biotechnology Trust PLC raised its stake in shares of BioMarin Pharmaceutical by 49.0% during the 2nd quarter. International Biotechnology Trust PLC now owns 97,284 shares of the biotechnology company’s stock worth $9,164,000 after buying an additional 32,000 shares during the last quarter. Canada Pension Plan Investment Board raised its stake in shares of BioMarin Pharmaceutical by 68.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 427,999 shares of the biotechnology company’s stock worth $40,318,000 after buying an additional 173,850 shares during the last quarter. Finally, Gideon Capital Advisors Inc. acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth $411,000.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Further Reading: How Do Tariffs Affect Trade Balances?

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.